<DOC>
	<DOCNO>NCT01014260</DOCNO>
	<brief_summary>Cardiovascular disease , specifically atherosclerosis , major cause mortality SLE develop country . In recent study investigator show high sensitivity C reactive protein ( hs-CRP ) high SLE patient ( versus without ) coronary calcium , measure subclinical atherosclerosis . In ongoing two year intervention trial atorvastatin , investigator determine statin retard coronary calcium reduce hs-CRP . However , 10 % patient trial intolerant statin . The investigator want investigate whether additional , potentially safe way , reduce hs-CRP SLE . In study , investigator determine doxycycline reduces hs-CRP vascular inflammatory marker include interleukin 6 ( IL-6 ) , soluble vascular cell adhesion molecule ( sVCAM-1 ) , soluble inter cell adhesion molecule ( s-ICAM-1 ) matrix metalloproteinase 9 ( MMP-9 ) SLE .</brief_summary>
	<brief_title>Doxycycline Outcomes Lupus Erythematosus</brief_title>
	<detailed_description />
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Doxycycline</mesh_term>
	<criteria>1 . Patients clinical diagnosis SLE , hsCRP &gt; 3mg/L , ( high risk level ) last 3 month , eligible . 2 . Patients must 18 year age old able give inform consent . 3 . Contraception OCPs necessary woman risk pregnancy . 1 . SLE patient allergic doxycycline tetracycline . 2 . Patients pregnant plan become pregnant . 3 . Patients oral contraceptive ( method contraception OCPs use . 4 . Tetracycline use within previous 2 week enrollment . 5 . Patients currently statins exclude , statin might reduce h CRP . 6 . Patients warfarin . 7 . Patients whose recent EKG show significant cardiac dysrhythmias heart block .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>Inflammatory marker cardiovascular disease</keyword>
</DOC>